Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humatrope ® (somatropin)
Humatrope® (somatropin): Interaction with other medicinal products
Humatrope (somatropin) may interact with other medicines
Concomitant treatment with glucocorticoids inhibits the growth-promoting effects of somatropin. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth. Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective.
In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal.
Somatropin can increase cytochrome P450 (CYP) enzyme activity in humans and may result in reduced plasma concentrations and decreased effectiveness of drugs metabolised by CYP3A such as sex steroids, corticosteroids, cyclosporine and anticonvulsants.
Humatrope Summary of Product Characteristics
Date of Last Review: April 05, 2019